• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 17, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

‘Educating’ patients’ immune cells may help combat diabetes

Bioengineer by Bioengineer
July 7, 2017
in Health
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New research reveals that a treatment called Stem Cell Educator therapy is safe and effective for treating type 1 and type 2 diabetes. The therapy cultures the patient's immune cells with cord blood stem cells and returns only the "educated" immune cells to the patient's circulation.

The strategy may provide benefits because abnormalities in multiple types of immune cells contribute to the autoimmunity in type1diabetes and the insulin resistance in type 2 diabetes.

"Current mechanistic studies demonstrated that platelets and their released mitochondria may contribute to the long-lasting clinical improvement of islet beta cell function in type 1 and 2 diabetic patients after Stem Cell Educator therapy," said Dr. Yong Zhao, lead author of the Stem Cells Translational Medicine study. "This therapy can also be applied to treat other autoimmune and inflammation-related diseases."

###

Editor's Note: This is a Cord Blood Association member paper.

Media Contact

Penny Smith
[email protected]

http://newsroom.wiley.com/

http://dx.doi.org/10.1002/sctm.0078

Share12Tweet7Share2ShareShareShare1

Related Posts

Substrate Stiffness Influences Neat1 and PSPC1 Regulation

November 17, 2025

Proceed with Care: Ketamine Use in Mental Health

November 17, 2025

Exploring TMAO, MicroRNAs, and Microbiomes in Heart Disease

November 17, 2025

Gene Editing Breakthroughs for Collagen Disorders Ahead

November 16, 2025
Please login to join discussion

POPULAR NEWS

  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    210 shares
    Share 84 Tweet 53
  • New Research Unveils the Pathway for CEOs to Achieve Social Media Stardom

    201 shares
    Share 80 Tweet 50
  • Neurological Impacts of COVID and MIS-C in Children

    89 shares
    Share 36 Tweet 22
  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1307 shares
    Share 522 Tweet 326

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Exploring LncRNA’s Role in Sugar Beet’s Low Nitrogen Response

Substrate Stiffness Influences Neat1 and PSPC1 Regulation

Proceed with Care: Ketamine Use in Mental Health

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.